However, initially they were struck not really by a notable difference but by a common characteristic: they discovered that both healthy and diseased cells included the defective protein form progerin, albeit not at the same amounts. ‘Progerin is also stated in healthy cells, probably as a byproduct. A well-functioning cellular waste materials disposal system can breakdown these small levels of progerin,’ says Djabali. The scientists found, however, 10 to 20 times even more progerin in the nuclei of diseased cells – a huge backlog of debris that should be removed.Unfortunately, nevertheless, the yield in the GlycoVaxyn procedure was too low. The vaccine producer needed the aid of experts to upscale their procedure so that it could be found in bioreactors. Their search found a finish in Empa’s Biomaterials laboratory, where both necessary know-how and the bioreactors had been at hand. It isn’t a issue of multiplying everything by 100 simply,’ explains Empa professional Julian Ihssen .’On a big level everything becomes more challenging.